Search

Your search keyword '"Regev, Arie"' showing total 332 results
Start Over Author "Regev, Arie"
332 results on '"Regev, Arie"'

4. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report

Author

Andrade, Raúl J., Aithal, Guruprasad P., de Boer, Ynto S., Liberal, Rodrigo, Gerbes, Alexander, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph, Kleiner, David E., De Martin, Eleonora, Kullak-Ublick, Gerd A., Stirnimann, Guido, Devarbhavi, Harshad, Vierling, John M., Manns, Michael P., Sebode, Marcial, Londoño, Maria Carlota, Avigan, Mark, Robles-Diaz, Mercedes, García-Cortes, Miren, Atallah, Edmond, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J., Hayashi, Paul H., Taubert, Richard, Fontana, Robert J., Weber, Sabine, Oo, Ye Htun, Zen, Yoh, Licata, Anna, Lucena, M Isabel, Mieli-Vergani, Giorgina, Vergani, Diego, and Björnsson, Einar S.

Published
2023
Full Text
View/download PDF

5. Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients.

Author

Fettiplace, Anna, Marcinak, John, Merz, Michael, Zhang, Hui‐Talia, Kikuchi, Luciana, Regev, Arie, Palmer, Melissa, Rockey, Don, Fontana, Robert, Hayashi, Paul H., Tillmann, Hans L., Di Bisceglie, Adrian M., and Lewis, James H.

Subjects
LITERATURE reviews, CANCER patients, ANTINEOPLASTIC agents, CONSORTIA, CLINICAL trials
Abstract

Summary: Background: Drug‐induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have abnormal liver tests pre‐treatment or on‐study for many reasons including liver injury due to past oncology treatments, hepatic metastases, medical co‐morbidities such as heart failure, and concomitant medications. At present, there are no regulatory guidelines or position papers that systematically address best practices pertaining to DILI detection, assessment and management in oncology patients. Aims: The goals of this review are (1) to examine and interpret the available evidence and (2) to make recommendations for detection, monitoring, adjudication, and management of suspected hepatocellular DILI during oncology clinical trials. Methods: This manuscript was developed by the IQ Consortium (International Consortium for Innovation and Quality in pharmaceutical development) DILI Initiative that consists of members from 17 pharmaceutical companies, in collaboration with academic and regulatory DILI experts. The manuscript is based on extensive literature review, expert interpretation of the literature, and several rounds of consensus discussions. Results: This review highlights recommendations for patient eligibility for clinical trials with or without primary/metastatic liver involvement, as well as changes in liver tests that should trigger increased monitoring and/or discontinuation of study drug. Guidance regarding causality assessment for suspected DILI events, rechallenge and dose‐modification is provided. Conclusions: This review brings together evidence‐based recommendations and expert opinion to provide the first dedicated consensus for best practices in detection, assessment, and management of DILI in oncology clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development

Author

Regev, Arie, Avigan, Mark I., Kiazand, Alexandre, Vierling, John M., Lewis, James H., Omokaro, Stephanie O., Di Bisceglie, Adrian M., Fontana, Robert J., Bonkovsky, Herbert L., Freston, James W., Uetrecht, Jack P., Miller, Ethan D., Pehlivanov, Nonko D., Haque, Syed Asif, Harrison, Melanie J., Kullak-Ublick, Gerd A., Li, Hewei, Patel, Niti N., Patwardhan, Meenal, Price, Karen D., Watkins, Paul B., and Chalasani, Naga P.

Published
2020
Full Text
View/download PDF

8. Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study

Author

Datta‐Mannan, Amita, primary, Regev, Arie, additional, Coutant, David E., additional, Dropsey, Andrew J., additional, Foster, Joanne, additional, Jones, Spencer, additional, Poorbaugh, Josh, additional, Schmitz, Carsten, additional, Wang, Evan, additional, and Woodman, Michael E., additional

Published
2024
Full Text
View/download PDF

9. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

Author

Treem, William R., Palmer, Melissa, Lonjon-Domanec, Isabelle, Seekins, Daniel, Dimick-Santos, Lara, Avigan, Mark I., Marcinak, John F., Dash, Ajit, Regev, Arie, Maller, Eric, Patwardhan, Meenal, Lewis, James H., Rockey, Don C., Di Bisceglie, Adrian M., Freston, James W., Andrade, Raul J., and Chalasani, Naga

Published
2021
Full Text
View/download PDF

10. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum

Author

Palmer, Melissa, primary, Kleiner, David E., additional, Goodman, Zachary, additional, Brunt, Elizabeth, additional, Avigan, Mark I., additional, Regev, Arie, additional, Hayashi, Paul H., additional, Lewis, James H., additional, Mehta, Ruby, additional, Harrison, Stephen A., additional, Siciliano, Massimo, additional, McWherter, Charles A., additional, Vuppalanchi, Raj, additional, Behling, Cynthia, additional, Miller, Veronica, additional, Chalasani, Naga, additional, and Sanyal, Arun J., additional

Published
2023
Full Text
View/download PDF

12. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.

Author

Palmer, Melissa, Kleiner, David E., Goodman, Zachary, Brunt, Elizabeth, Avigan, Mark I., Regev, Arie, Hayashi, Paul H., Lewis, James H., Mehta, Ruby, Harrison, Stephen A., Siciliano, Massimo, McWherter, Charles A., Vuppalanchi, Raj, Behling, Cynthia, Miller, Veronica, Chalasani, Naga, and Sanyal, Arun J.

Subjects
LIVER biopsy, LIVER injuries, CLINICAL trials, FATTY liver, DRUG side effects, NATALIZUMAB
Abstract

Summary: Background: Causality assessment of suspected drug‐induced liver injury (DILI) during metabolic dysfunction‐associated steatohepatitis (MASH) clinical trials can be challenging, and liver biopsies are not routinely performed as part of this evaluation. While the field is moving away from liver biopsy as a diagnostic and prognostic tool, information not identified by non‐invasive testing may be provided on histology. Aim: To address the appropriate utilisation of liver biopsy as part of DILI causality assessment in this setting. Methods: From 2020 to 2022, the Liver Forum convened a series of webinars on issues pertaining to liver biopsy during MASH trials. The Histology Working Group was formed to generate a series of consensus documents addressing these challenges. This manuscript focuses on liver biopsy as part of DILI causality assessment. Results: Expert opinion, guidance and recommendations on the role of liver biopsy as part of causality assessment of suspected DILI occurring during clinical trials for a drug(s) being developed for MASH are provided. Lessons learned from prior MASH programs are reviewed and gaps identified. Conclusions: Although there are no pathognomonic features, histologic evaluation of suspected DILI during MASH clinical trials may alter patient management, define the pattern and severity of injury, detect findings that favour a diagnosis of DILI versus MASH progression, identify prognostic features, characterise the clinicopathological phenotype of DILI, and/or define lesions that influence decisions about trial discontinuation and further development of the drug. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report

Author

Andrade, Raúl J, Aithal, Guruprasad P; https://orcid.org/0000-0003-3924-4830, de Boer, Ynto S; https://orcid.org/0000-0002-4066-7593, Liberal, Rodrigo, Gerbes, Alexander; https://orcid.org/0000-0003-0440-7417, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph; https://orcid.org/0000-0002-4264-1928, Kleiner, David E; https://orcid.org/0000-0003-3442-4453, De Martin, Eleonora, Kullak-Ublick, Gerd A; https://orcid.org/0000-0002-0757-4408, Stirnimann, Guido; https://orcid.org/0000-0002-8215-4489, Devarbhavi, Harshad; https://orcid.org/0000-0002-3593-3746, Vierling, John M, Manns, Michael P, Sebode, Marcial; https://orcid.org/0000-0002-5163-6979, Londoño, Maria Carlota, Avigan, Mark, Robles-Diaz, Mercedes; https://orcid.org/0000-0002-2365-2787, García-Cortes, Miren, Atallah, Edmond; https://orcid.org/0000-0002-7341-9174, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J, Hayashi, Paul H; https://orcid.org/0000-0002-5371-1020, Taubert, Richard; https://orcid.org/0000-0001-9270-2496, Fontana, Robert J, Weber, Sabine; https://orcid.org/0000-0001-7077-8078, Oo, Ye Htun; https://orcid.org/0000-0002-0495-6734, Zen, Yoh; https://orcid.org/0000-0001-8370-6508, et al, IAIHG Consortium, EASL DHILI Consortium, Andrade, Raúl J, Aithal, Guruprasad P; https://orcid.org/0000-0003-3924-4830, de Boer, Ynto S; https://orcid.org/0000-0002-4066-7593, Liberal, Rodrigo, Gerbes, Alexander; https://orcid.org/0000-0003-0440-7417, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph; https://orcid.org/0000-0002-4264-1928, Kleiner, David E; https://orcid.org/0000-0003-3442-4453, De Martin, Eleonora, Kullak-Ublick, Gerd A; https://orcid.org/0000-0002-0757-4408, Stirnimann, Guido; https://orcid.org/0000-0002-8215-4489, Devarbhavi, Harshad; https://orcid.org/0000-0002-3593-3746, Vierling, John M, Manns, Michael P, Sebode, Marcial; https://orcid.org/0000-0002-5163-6979, Londoño, Maria Carlota, Avigan, Mark, Robles-Diaz, Mercedes; https://orcid.org/0000-0002-2365-2787, García-Cortes, Miren, Atallah, Edmond; https://orcid.org/0000-0002-7341-9174, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J, Hayashi, Paul H; https://orcid.org/0000-0002-5371-1020, Taubert, Richard; https://orcid.org/0000-0001-9270-2496, Fontana, Robert J, Weber, Sabine; https://orcid.org/0000-0001-7077-8078, Oo, Ye Htun; https://orcid.org/0000-0002-0495-6734, Zen, Yoh; https://orcid.org/0000-0001-8370-6508, et al, IAIHG Consortium, and EASL DHILI Consortium

Abstract

Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition.

Published
2023

15. Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry

Author

Wickremsinhe, Enaksha, primary, Fantana, Antoniu, additional, Berthier, Erwin, additional, Quist, Brook A, additional, Lopez de Castilla, Diego, additional, Fix, Charles, additional, Chan, Kahlil, additional, Shi, Jing, additional, Walker, Michael G, additional, Kherani, Jennifer F, additional, Knoderer, Holly, additional, Regev, Arie, additional, and Harding, James J, additional

Published
2022
Full Text
View/download PDF

19. Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry.

Author

Wickremsinhe, Enaksha, Fantana, Antoniu, Berthier, Erwin, Quist, Brook A, Lopez de Castilla, Diego, Fix, Charles, Chan, Kahlil, Shi, Jing, Walker, Michael G, Kherani, Jennifer F, Knoderer, Holly, Regev, Arie, and Harding, James J

Subjects
BLOOD collection, VENOUS puncture, ALKALINE phosphatase, ALANINE aminotransferase, PATIENT experience, LIVER, ASPARTATE aminotransferase
Abstract

Background: Abnormal liver function is a common manifestation of human disease and may also occur in approved and investigational medications as drug-induced liver injury (DILI). Capillary blood collection devices may allow for more frequent and convenient measurement outside of the clinic. Validation of such approaches is lacking. Methods: This prospective, biospecimens collection study evaluated the Tasso+ in patients with abnormal liver tests (NCT05259618). The primary objective was to define the concordance of alanine aminotransferase (ALT) obtained via Tasso+ compared to standard venipuncture. Secondary objectives included measurement of 14 other analytes and patient surveys. At the time of venipuncture, 2 Tasso+ samples were collected: one was centrifuged and shipped, and the other was refrigerated and shipped as whole blood. Results: Thirty-six patients with elevated ALT values were enrolled. In total, 100 venipuncture, 50 Tasso+ centrifuged, and 48 Tasso+ whole blood samples were obtained. Tasso+ centrifuged samples demonstrated concordance correlation coefficients (CCC) of >0.99 for ALT, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and total bilirubin and CCC >0.95 for albumin, chloride, enzymatic creatinine, serum glucose, magnesium, and phosphorus. Tasso+ whole blood showed CCC of >0.99 for AST, bilirubin total, and enzymatic creatinine and CCC >0.95 for ALT, ALP, albumin, magnesium, and phosphorus. Hemolysis was comparable across the 3 sample types, but its impact was reflected in the Tasso+ potassium data. Patient feedback indicated a very favorable patient experience. Conclusions: The capillary blood collection device, Tasso+, showed substantial to almost perfect concordance to standard venipuncture for measurement of abnormal liver function. Studies are ongoing to validate longitudinal sampling outside of the clinic. Clinicaltrials.gov Registration Number: NCT05259618 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Author

Fouad, Yasser, primary, Palmer, Melissa, additional, Chen, Minjun, additional, Regev, Arie, additional, Banerjee, Rajarshi, additional, Myers, Rob, additional, Riccio, Robert, additional, Torstenson, Richard, additional, Younes, Ramy, additional, Arora, Puneet S., additional, Landgren, Henrik, additional, Karsdal, Morten A., additional, Blake, Martin, additional, Shapiro, David A., additional, Gruss, Hans-Juergen, additional, Sheikh, Muhammad Y., additional, Attia, Dina, additional, Bollipo, Steven, additional, Smith, Alastair D., additional, Freilich, Bradley, additional, Gish, Robert G., additional, and Schuppan, Detlef, additional

Published
2021
Full Text
View/download PDF

23. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease

Author

Palmer, Melissa, Regev, Arie, Lindor, Keith, Avigan, Mark I., Dimick‐Santos, Lara, Treem, William, Marcinak, John F., Lewis, James H., Anania, Frank A., Seekins, Daniel, Shneider, Benjamin L., Chalasani, Naga, Dash, Ajit, Krishna, Gopal, Lonjon‐Domanec, Isabelle, Maller, Eric, Patel, Niti, Patwardhan, Meenal, Raheja, Ritu, Lilly, Eli, Treem, William R., Wuchter‐Czerwony, Christian, and Zhang, Hui‐Talia

Subjects
Drug, Adult, medicine.medical_specialty, Societies, Pharmaceutical, Consensus, Drug Industry, media_common.quotation_subject, Best practice, MEDLINE, Review Article, Primary sclerosing cholangitis, 03 medical and health sciences, 0302 clinical medicine, Liver Function Tests, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, media_common, Liver injury, Clinical Trials as Topic, Cholestasis, Hepatology, medicine.diagnostic_test, business.industry, Liver Cirrhosis, Biliary, Gastroenterology, Consensus Guidelines, medicine.disease, Discontinuation, Clinical trial, Liver, Chronic Disease, 030211 gastroenterology & hepatology, Chemical and Drug Induced Liver Injury, Liver function tests, business
Abstract

Background Improved knowledge of the molecular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to an increased interest in developing novel therapies. Patients with cholestatic liver disease often require different approaches to assessment and management of suspected drug-induced liver injury (DILI) compared to those with healthy livers and those with parenchymal liver diseases. At present, there are no regulatory guidelines or society position papers, that systematically address best practices pertaining to detection of DILI in these patients. Aims To outline best practices for detection, assessment and management of suspected acute DILI during clinical trials in adults with the cholestatic liver diseases - Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). Methods This is one of the several papers developed by the IQ DILI Initiative, which is comprised of members from 16 pharmaceutical companies, in collaboration with DILI experts from academia and regulatory agencies. The contents are the result of an extensive literature review, as well as in-depth discussions among industry, regulatory and academic DILI experts, to achieve consensus recommendations on DILI-related issues occurring during clinical trials for cholestatic liver diseases. Results Recommended best practices are outlined pertaining to hepatic eligibility criteria, monitoring of liver tests, approach to a suspected DILI signal, and hepatic discontinuation rules. Conclusions This paper provides a framework for the approach to detection, assessment and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver disease.

Published
2019

24. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum

Author

Cheung, Amanda, Neuschwander-Tetri, Brent A., Kleiner, David E., Schabel, Elmer, Rinella, Mary, Harrison, Stephen, Ratziu, Vlad, Sanyal, Arun J., Loomba, Rohit, Megnien, Sophie Jeannin, Torstenson, Richard, Miller, Veronica, Abdelmalek, Manal, Anstee, Quentin, Banerjee, Rajarshi, Bashir, Mustafa, Bedossa, Pierre, Berner-Hansen, Mark, Chakravarthy, Manu, Charles, Edgar, Dimick-Santos, Lara, Ertle, Judith, Francque, Sven, Friedman, Scott, Gannedahl, Goran, Greene, Katherine, Hambleton, Michael, Hum, Dean, Imperial, Joanne, Leeming, Diana Julie, Mehta, Ruby, Naoumov, Nikolai, Omokaro, Stephanie, Palmer, Melissa, Peres, Dan, Powell, Margaret, Regev, Arie, Rosen, Glenn, Sanyal, Arun, Schoelch, Corinna, Schwimmer, Jeffrey, Shringarpure, Reshma, Schwander-Tetri, Brent Neu, Ukomadu, Chinweike, Wong, Vincent, Wright, Teresa, Chan, Jean, Tai, Dean, and Liver Forum Case Definitions Worki

Subjects
Liver Cirrhosis, 0301 basic medicine, medicine.medical_specialty, Cirrhosis, medicine.medical_treatment, Population, MEDLINE, Disease, Liver transplantation, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Severity of illness, medicine, Humans, Regulatory science, Intensive care medicine, education, Clinical Trials as Topic, education.field_of_study, Hepatology, business.industry, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030211 gastroenterology & hepatology, Human medicine, business
Abstract

Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%-2% of the population in developed nations at risk of developing NASH cirrhosis and its complications. The design of NASH clinical therapeutic trials is hampered by the long period of minimally symptomatic disease that typically precedes the development of decompensated cirrhosis and the accompanying uncertainties regarding the best precirrhotic trial endpoints that reliably reflect a subsequent reduction in liver-related morbidity and mortality. The Liver Forum is a multistakeholder organization comprised of academic, industry, and regulatory experts working from a regulatory science perspective to identify barriers, prioritize research, and identify solutions to accelerate therapeutic development for NASH. Past work of The Liver Forum has focused on recommendations for disease definitions and baseline parameters to be implemented in clinical trials that are designed to assess disease status and prevent progression to cirrhosis, liver transplantation, hepatocellular carcinoma, and death. The purpose of this summary is to review currently available clinical data to identify parameters that change in parallel with liver histology and are likely to reflect clinically meaningful reductions in the risk of developing cirrhosis and its complications. We review available data on exploratory histological, blood-based, and imaging pharmacodynamic biomarkers that may reflect meaningful treatment responses and provide recommendations regarding measurements to be considered in phase 2 and 3 trials as well as during postmarketing monitoring trials.

Published
2019
Full Text
View/download PDF

33. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

Author

Treem, William R., primary, Palmer, Melissa, additional, Lonjon-Domanec, Isabelle, additional, Seekins, Daniel, additional, Dimick-Santos, Lara, additional, Avigan, Mark I., additional, Marcinak, John F., additional, Dash, Ajit, additional, Regev, Arie, additional, Maller, Eric, additional, Patwardhan, Meenal, additional, Lewis, James H., additional, Rockey, Don C., additional, Di Bisceglie, Adrian M., additional, Freston, James W., additional, Andrade, Raul J., additional, and Chalasani, Naga, additional

Published
2020
Full Text
View/download PDF

34. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum

Author

Noureddin, Mazen, primary, Chan, Jean L., additional, Barradas, Katherine, additional, Dimick-Santos, Lara, additional, Schabel, Elmer, additional, Omokaro, Stephanie O., additional, Anania, Frank A., additional, Myers, Robert P., additional, Miller, Veronica, additional, Sanyal, Arun J., additional, Chalasani, Naga, additional, Bajaj, Jasmohan, additional, Berzigotti, Annalisa, additional, Birman, Pascal, additional, Bosch, Jaime, additional, Brower, Ashley, additional, Calboli, Dania, additional, Charlton, William, additional, Dickinson, Klara, additional, Filozof, Claudia, additional, Forsgren, Mikael F., additional, Fuchs, Michael, additional, Garcia-Tsao, Guadalupe, additional, Gonzalez-Abraldes, Juan, additional, Gruss, Hans-Juergen, additional, Hansen, Morten, additional, Hosman, Suneil, additional, Imperial, Joanne, additional, Jones, David, additional, Lalazar, Gadi, additional, Leinhard, Olof Dahlqvist, additional, Lyons, Erica, additional, McColgan, Brian, additional, Mehta, Ruby, additional, Mesenbrink, Peter, additional, Myers, Rob, additional, Noureddin, Mazen, additional, Pei, Veronica, additional, Ratziu, Vlad, additional, Regev, Arie, additional, Riccio, Robert, additional, Sanyal, Arun, additional, Seo, Suna, additional, Smith, Alastair, additional, Szitanyi, Peter, additional, and Traber, Peter, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results